Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Engaging communities in therapeutics clinical research during pandemics: Experiences and lessons from the ACTIV COVID-19 therapeutics research initiative.
Wohl DA, Adam SJ, Gibbs KW, Moskowitz AL, Ortel TL, Singh U, Jilg N, Evering TH, Fischer WA 2nd, Taiwo BO, Daar ES, Lindsell CJ, Naggie S, Rothman RL, Dunsmore SE, McAdams MP, Vail J, Jayaweera D. Wohl DA, et al. Among authors: fischer wa 2nd. J Clin Transl Sci. 2024 Oct 15;8(1):e156. doi: 10.1017/cts.2024.561. eCollection 2024. J Clin Transl Sci. 2024. PMID: 39540112 Free PMC article. Review.
Health and economic impacts of Lassa vaccination campaigns in West Africa.
Smith DRM, Turner J, Fahr P, Attfield LA, Bessell PR, Donnelly CA, Gibb R, Jones KE, Redding DW, Asogun D, Ayodeji OO, Azuogu BN, Fischer WA 2nd, Jan K, Olayinka AT, Wohl DA, Torkelson AA, Dinkel KA, Nixon EJ, Pouwels KB, Hollingsworth TD. Smith DRM, et al. Among authors: fischer wa 2nd. Nat Med. 2024 Aug 28. doi: 10.1038/s41591-024-03232-y. Online ahead of print. Nat Med. 2024. PMID: 39198710
Host response to influenza infections in human blood: association of influenza severity with host genetics and transcriptomic response.
Schughart K, Smith AM, Tsalik EL, Threlkeld SC, Sellers S, Fischer WA 2nd, Schreiber J, Lücke E, Cornberg M, Debarry J, Woods CW, McClain MT, Heise M. Schughart K, et al. Among authors: fischer wa 2nd. Front Immunol. 2024 Aug 13;15:1385362. doi: 10.3389/fimmu.2024.1385362. eCollection 2024. Front Immunol. 2024. PMID: 39192977 Free PMC article.
Tecovirimat for Mpox-Promise and Limitations.
Zucker J, Fischer WA 2nd, Wilkin T. Zucker J, et al. Among authors: fischer wa 2nd. JAMA Intern Med. 2024 Mar 1;184(3):279-280. doi: 10.1001/jamainternmed.2023.7693. JAMA Intern Med. 2024. PMID: 38190299 No abstract available.
A prospective, multi-site, cohort study to estimate incidence of infection and disease due to Lassa fever virus in West African countries (the Enable Lassa research programme)-Study protocol.
Penfold S, Adegnika AA, Asogun D, Ayodeji O, Azuogu BN, Fischer WA 2nd, Garry RF, Grant DS, Happi C, N'Faly M, Olayinka A, Samuels R, Sibley J, Wohl DA, Accrombessi M, Adetifa I, Annibaldis G, Camacho A, Dan-Nwafor C, Deha ARE, DeMarco J, Duraffour S, Goba A, Grais R, Günther S, Honvou ÉJJP, Ihekweazu C, Jacobsen C, Kanneh L, Momoh M, Ndiaye A, Nsaibirni R, Okogbenin S, Ochu C, Ogbaini E, Logbo ÉPMA, Sandi JD, Schieffelin JS, Verstraeten T, Vielle NJ, Yadouleton A, Yovo EK; Enable Protocol authorship group. Penfold S, et al. Among authors: fischer wa 2nd. PLoS One. 2023 Mar 30;18(3):e0283643. doi: 10.1371/journal.pone.0283643. eCollection 2023. PLoS One. 2023. PMID: 36996258 Free PMC article.
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection.
Boucau J, Chew KW, Choudhary MC, Deo R, Regan J, Flynn JP, Crain CR, Hughes MD, Ritz J, Moser C, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Coombs RW, Fischer WA 2nd, Daar ES, Wohl DA, Eron JJ, Currier JS, Smith DM; POSITIVES study team; Li JZ, Barczak AK; ACTIV-2/A5401 Study Team. Boucau J, et al. Among authors: fischer wa 2nd. Cell Rep Med. 2022 Jul 19;3(7):100678. doi: 10.1016/j.xcrm.2022.100678. Epub 2022 Jun 20. Cell Rep Med. 2022. PMID: 35793677 Free PMC article. Clinical Trial.
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection.
Boucau J, Chew KW, Choudhary M, Deo R, Regan J, Flynn JP, Crain CR, Hughes MD, Ritz J, Moser C, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Coombs RW, Fischer WA 2nd, Daar ES, Wohl DA, Eron JJ, Currier JS, Smith DM, Li JZ, Barczak AK; ACTIV-2/A5401 Study Team. Boucau J, et al. Among authors: fischer wa 2nd. medRxiv [Preprint]. 2021 Dec 30:2021.12.25.21268211. doi: 10.1101/2021.12.25.21268211. medRxiv. 2021. Update in: Cell Rep Med. 2022 Jul 19;3(7):100678. doi: 10.1016/j.xcrm.2022.100678 PMID: 35018382 Free PMC article. Updated. Preprint.
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus.
Fischer WA 2nd, Eron JJ Jr, Holman W, Cohen MS, Fang L, Szewczyk LJ, Sheahan TP, Baric R, Mollan KR, Wolfe CR, Duke ER, Azizad MM, Borroto-Esoda K, Wohl DA, Coombs RW, James Loftis A, Alabanza P, Lipansky F, Painter WP. Fischer WA 2nd, et al. Sci Transl Med. 2022 Jan 19;14(628):eabl7430. doi: 10.1126/scitranslmed.abl7430. Epub 2022 Jan 19. Sci Transl Med. 2022. PMID: 34941423 Free PMC article. Clinical Trial.
45 results